All In Biotech

Drug Trial Radar · NCT01144637

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects

Last checked: Nov 19, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,005 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,005

Actual

Start

Feb 2013

Primary completion

Nov 2013

Study completion Jun 2014

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
First posted
Jun 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.

Conditions

  • Smallpox

Interventions

  • IMVAMUNE®Biological

    0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)

  • PlaceboOther

    0.5 ml TBS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PRNT GMTTime frame: 2 weeks following the second vaccination

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Vaccine Research Clinic

    Birmingham, Alabama

  • Anaheim Clinical Trials

    Anaheim, California

  • National Research Institute

    Los Angeles, California

  • Northern California Clinical Research Center (NCCRC)

    Redding, California

  • Therapeutics Clinical Research

    San Diego, California

  • Lynn Institute of the Rockies

    Colorado Springs, Colorado

  • Avail Clinical Research, LLC

    DeLand, Florida

  • Broward Research Group

    Hollywood, Florida

  • Accelovance Melbourne

    Melbourne, Florida

  • Southeast Regional Research Group

    Savannah, Georgia

  • Advanced Clinical Research, Inc.

    Meridian, Idaho

  • Accelovance Peoria

    Peoria, Illinois

  • Heartland Research Associates

    Augusta, Kansas

  • Heartland Research Associates, LLC

    Wichita, Kansas

  • Benchmark Research

    Metairie, Louisiana

  • QPS Bio-Kinetic

    Springfield, Missouri

  • Washington University in St. Louis, School of Medicine

    St Louis, Missouri

  • Meridian Clinical Research, LLC

    Omaha, Nebraska

  • Clinical Research Center of Nevada, LLC

    Las Vegas, Nevada

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • Wake Research Associates

    Raleigh, North Carolina

  • Rapid Medical Research, Inc.

    Cleveland, Ohio

  • Family Practice Center of Wooster

    Wooster, Ohio

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Columbia Research Group, Inc.

    Portland, Oregon

  • Omega Medical Research

    Warwick, Rhode Island

  • PMG Research of Charleston

    Mt. Pleasant, South Carolina

  • Holston Medical Group

    Bristol, Tennessee

  • Volunteer Research Group

    Knoxville, Tennessee

  • Benchmark Research

    Fort Worth, Texas

  • Tanner Clinic

    Layton, Utah

  • Advanced Clinical Research

    West Jordan, Utah

  • Clinical Research Associates of Tidewater

    Norfolk, Virginia

  • University Physicians Internal Medicine University Physicians & Surgeons, Inc.

    Huntington, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.